PLUS1
0.25
-0.015 (-5.66%)
-0.015 (-5.66%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Onconova Therapeutics Inc | ONTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.015 | -5.66% | 0.25 | 19:17:53 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 0.26 | 0.245 | 0.275 | 0.27 | 0.265 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.25 | 0.26 | 0.01 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8,155 | 5,407,347 | $ 0.260638 | $ 1,409,360 | 16,735,540 | 0.1027 - 1.56 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:17:53 | formt | 1,898 | $ 0.25 | USD |
Onconova Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 47.11M | 183.58M | 182.00M | $ 2.18M | $ - | -1.50 | 0.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Onconova Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/13/2020 | 08:00 | GlobeNewswire Inc. | Onconova Therapeutics to Present Update During the 2020 BIO.. |
| 10/09/2020 | 17:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/21/2020 | 08:00 | GlobeNewswire Inc. | Onconova Therapeutics Announces Initiation of a Phase 1.. |
| 9/09/2020 | 08:00 | GlobeNewswire Inc. | Onconova Therapeutics Announces Participation at Upcoming.. |
| 8/31/2020 | 16:50 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/31/2020 | 16:43 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/31/2020 | 08:24 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.285 | 0.2869 | 0.242 | 0.2614253 | 5,317,041 | -0.035 | -12.28% |
| 1 Month | 0.2575 | 0.342 | 0.242 | 0.2972514 | 7,927,417 | -0.0075 | -2.91% |
| 3 Months | 1.03 | 1.20 | 0.1901 | 0.3609668 | 17,667,199 | -0.78 | -75.73% |
| 6 Months | 0.342 | 1.56 | 0.1901 | 0.5666689 | 16,251,474 | -0.092 | -26.9% |
| 1 Year | 0.55 | 1.56 | 0.1027 | 0.4831235 | 15,722,168 | -0.30 | -54.55% |
| 3 Years | 33.90 | 39.975 | 0.1027 | 1.01 | 5,722,641 | -33.65 | -99.26% |
| 5 Years | 21.00 | 122.55 | 0.1027 | 1.51 | 3,505,479 | -20.75 | -98.81% |
Onconova Therapeutics Description
| Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks signaling by targeting RAS effeccellular tor pathways. |
